Daito Pharmaceutical

4577.TPharmaceutical

Filed as Daito Pharmaceutical Co.,Ltd. (2022-08–2026-08)

Key numbers · FY ended 2026-05

Revenue¥50.6bn+0.0% YoY Operating income¥3.6bn+38.9% YoY Net income (owners)¥3.2bn+65.7% YoY Total assets¥73.3bn-6.0% YoY EPS (basic)¥107.49+71.3% YoY

Full financial history and reports →

Stock price4577 · View chart ↗

Open the price chart on TradingView.

Latest filings

Tue, Nov 10 · JST1 filing

16:035% STAKEDaito Pharmaceutical · Kaname Capital, L.P. · 11.13% → 12.13%+1.00pp

Tue, Oct 13 · JST1 filing

16:075% STAKEDaito Pharmaceutical · Kaname Capital, L.P. · 11.13% → 12.13%+1.00pp

Tue, Aug 12 · JST1 filing

11:415% STAKEDaito Pharmaceutical · Kaname Capital, L.P. · 9.98% → 11.13%+1.15pp

Fri, Jan 17 · JST1 filing

17:04MATERIALDaito Pharmaceutical · Change in parent company or specified subsidiary

Wed, Aug 28 · JST1 filing

16:43MATERIALDaito Pharmaceutical · Change in major shareholder

All filings →

Major holders (5%+) · 1

Holder	Stake	Change	Filed
Kaname Capital, L.P.	12.13%	+1.00pp	2026-11-10

Each holder's own ratio from its most recent large-shareholding report.